Maxigen Biotech Inc
TWSE:1783

Watchlist Manager
Maxigen Biotech Inc Logo
Maxigen Biotech Inc
TWSE:1783
Watchlist
Price: 46.9 TWD Market Closed
Market Cap: 4.2B TWD
Have any thoughts about
Maxigen Biotech Inc?
Write Note

Maxigen Biotech Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Maxigen Biotech Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Maxigen Biotech Inc
TWSE:1783
Income from Continuing Operations
NT$155.3m
CAGR 3-Years
18%
CAGR 5-Years
21%
CAGR 10-Years
63%
G
Grape King Bio Ltd
TWSE:1707
Income from Continuing Operations
NT$2.2B
CAGR 3-Years
5%
CAGR 5-Years
3%
CAGR 10-Years
5%
Maywufa Co Ltd
TWSE:1731
Income from Continuing Operations
NT$172.9m
CAGR 3-Years
2%
CAGR 5-Years
14%
CAGR 10-Years
7%
Chlitina Holding Ltd
TWSE:4137
Income from Continuing Operations
NT$714.5m
CAGR 3-Years
-19%
CAGR 5-Years
-12%
CAGR 10-Years
0%
No Stocks Found

Maxigen Biotech Inc
Glance View

Market Cap
4.2B TWD
Industry
Consumer products

Maxigen Biotech, Inc. engages in the research, development, manufacturing, and sales of biomedical materials and beauty care products. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2011-05-18. The firm operates through two main segments. The Consumer Products segment is mainly engaged in the wholesales of cleansing products, facial care products, medical beauty products and others. The Biomedical Products is mainly involved in the manufacture and sales of Formagraft collagen and ceramic composite material products, Foramic ceramic bone feed materials, Artiaid hyaluronic acid joint injection products, ViscAid ophthalmology viscoelastic agents, as well as SurgiAid wound collagen materials and others.

Intrinsic Value
30.4 TWD
Overvaluation 35%
Intrinsic Value
Price

See Also

What is Maxigen Biotech Inc's Income from Continuing Operations?
Income from Continuing Operations
155.3m TWD

Based on the financial report for Sep 30, 2024, Maxigen Biotech Inc's Income from Continuing Operations amounts to 155.3m TWD.

What is Maxigen Biotech Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
63%

Over the last year, the Income from Continuing Operations growth was -19%. The average annual Income from Continuing Operations growth rates for Maxigen Biotech Inc have been 18% over the past three years , 21% over the past five years , and 63% over the past ten years .

Back to Top